Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug co... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
0
Authors
Charles Rudin
27 more
Charles Rudin
•
Bonnie Glisson
25 more
•
David Spigel
Published
December 5, 2016
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Epidemiology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(16)30565-4
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Epidemiology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(16)30565-4
Other Formats
PDF
